{"commentary":{"count":85,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":46,"youtube":24,"podcast":15},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04483739\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"IsKia","nct_id":"NCT04483739","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=iskia-nct04483739. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"IsKia","arms":[{"description":"4 28 day cycles of Carfilzomib = 20 mg/m2 IV on day 1 cycle 1 only, followed by 56 mg/m2 IV on days 8, 15 cycle 1 and on days 1, 8, 15 for cycles 2-4 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22","label":"Krd Induction","type":"EXPERIMENTAL"},{"description":"Isatuximab= 10 mg/kg IV on day 1, 8, 15, and 22 during Cycle 1, followed by 10 mg/kg IV on days 1 and 15 during Cycles 2 to 4.\n\nCarfilzomib = 20 mg/m2 IV on day 1 cycle 1 only, followed by 56 mg/m2 IV on days 8, 15 cycle 1 and on days 1, 8, 15 for cycles 2-4 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22","label":"Isa-KRd induction","type":"EXPERIMENTAL"},{"description":"4 28 day cycles of Carfilzomib = 56 mg/m2 IV on days 1, 8, 15 cycle 5-8 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22","label":"KRd post ASCT consolidation","type":"EXPERIMENTAL"},{"description":"4 28 day cycles of Isatuximab= 10 mg/kg IV on days 1 and 15 on cycles 5-8 Carfilzomib = 56 mg/m2 IV on days 1, 8, 15 cycle 5-8 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22","label":"Isa-KRd post ASCT consolidation:","type":"EXPERIMENTAL"},{"description":"12 28 day cycles of Carfilzomib = 56 mg/m2 IV on days 1, 15 Lenalidomide = 10 mg orally on days 1-21 Dexamethasone = 20 mg orally/IV on days 1, 15","label":"KRd light consolidation","type":"EXPERIMENTAL"},{"description":"Isatuximab= 10 mg/kg IV on day 1 Carfilzomib = 56 mg/m2 IV on days 1, 15 Lenalidomide = 10 mg orally on days 1-21 Dexamethasone = 20 mg orally/IV on days 1, 15","label":"Isa-KRd light consolidation","type":"EXPERIMENTAL"}],"collaborators":["EMN Trial Office S.r.l. Impresa Sociale","Sanofi","Amgen"],"completion_date":{"date":"2032-12-31","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":302,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Carfilzomib Lenalidomide Dexamethasone","type":"DRUG"},{"name":"Isatuximab Carfilzomib Lenalidomide Dexamethasone","type":"DRUG"}],"last_update":"2026-07-16","lead_sponsor":"European Myeloma Network B.V.","official_title":"Phase III Study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) Versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-07-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Rate of MRD negativity after ASCT consolidation treatment by NGS","timeFrame":"The end of consolidation, average of 12 months"}],"references":[{"citation":"Gay F, Roeloffzen W, Dimopoulos MA, Rosinol L, van der Klift M, Mina R, Oriol A, Katodritou E, Wu KL, Rodriguez Otero P, Hajek R, Antonioli E, van Duin M, D'Agostino M, Martinez-Lopez J, van Leeuwen-Segarceanu EM, Zamagni E, van de Donk NWCJ, Weisel KC, Pour L, Radocha J, Belotti A, Schjesvold F, Blade J, Einsele H, Sonneveld P, Boccadoro M, Broijl A. Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial. Nat Med. 2026 May;32(5):1773-1782. doi: 10.1038/s41591-026-04282-0. Epub 2026 Apr 6.","pmid":"41942646","type":"DERIVED"}],"start_date":{"date":"2020-09-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)","url":"https://clinicaltrials.gov/study/NCT04483739"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/iskia-nct04483739"}